Register for our free email digests:
Alder BioPharmaceuticals Inc.
www.alderbio.com
Latest From Alder BioPharmaceuticals Inc.
Amgen’s Playing To Its R&D Strengths, Which No Longer Include Neuroscience
The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.
Acorda Restructures, Cuts Jobs By 25% With No Deals, Big Debt On The Horizon
Acorda is cutting jobs to save $21m annually and otherwise lowering expenses for a total of $60m in reduced costs in 2020 to focus on marketing Inbrija, but looming overhead is $345m in debt due in 2021. Meanwhile, ex-US partners and company buyers appear nowhere in sight.
UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
- Synthesis Technologies, Production Processes
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Alder BioPharmaceuticals Inc.
- Senior Management
-
Robert W Azelby, CEO
Carlos Campoy, CFO
John A Latham, PhD, CSO
Nadia Dac, Chief Commercial Officer
Erin Lavelle, COO - Contact Info
-
Alder BioPharmaceuticals Inc.
Phone: (425) 205-2900
11804 North Creek Pkwy. S.
Bothell, WA 98011
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice